Kestra Advisory Services LLC grew its position in shares of DexCom, Inc. (NASDAQ:DXCM – Free Report) by 133.4% during the 3rd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 12,786 shares of the medical device company’s stock after buying an additional 7,309 shares during the quarter. Kestra Advisory Services LLC’s holdings in DexCom were worth $1,103,000 as of its most recent filing with the Securities & Exchange Commission.
A number of other hedge funds and other institutional investors have also recently modified their holdings of DXCM. Mather Group LLC. increased its position in shares of DexCom by 27.7% during the third quarter. Mather Group LLC. now owns 563 shares of the medical device company’s stock valued at $49,000 after acquiring an additional 122 shares during the last quarter. Fifth Third Wealth Advisors LLC lifted its holdings in DexCom by 2.8% during the third quarter. Fifth Third Wealth Advisors LLC now owns 5,510 shares of the medical device company’s stock worth $475,000 after acquiring an additional 150 shares during the period. Elevation Wealth Partners LLC lifted its holdings in DexCom by 61.0% during the third quarter. Elevation Wealth Partners LLC now owns 401 shares of the medical device company’s stock worth $35,000 after acquiring an additional 152 shares during the period. MassMutual Private Wealth & Trust FSB boosted its position in DexCom by 15.4% in the second quarter. MassMutual Private Wealth & Trust FSB now owns 1,147 shares of the medical device company’s stock worth $77,000 after purchasing an additional 153 shares during the last quarter. Finally, Simplicity Wealth LLC boosted its position in DexCom by 5.4% in the third quarter. Simplicity Wealth LLC now owns 3,169 shares of the medical device company’s stock worth $273,000 after purchasing an additional 162 shares during the last quarter. Hedge funds and other institutional investors own 97.75% of the company’s stock.
Wall Street Analysts Forecast Growth
A number of research analysts have issued reports on DXCM shares. Barclays upped their price objective on DexCom from $115.00 to $120.00 and gave the company an “overweight” rating in a research note on Friday, October 30th. Deutsche Bank lifted their target price on DexCom from $86.00 to $92.00 and gave the stock a “buy” rating in a research note on Friday, July 31st. TD Cowen reissued a “buy” rating and issued a $95.00 price target on shares of DexCom in a report on Friday, September 18th. Canaccord Genuity Group boosted their price target on shares of DexCom from $90.00 to $97.00 and gave the stock a “buy” rating in a report on Friday, October 30th. Finally, Rothschild & Co Redburn increased their price target on shares of DexCom from $90.00 to $100.00 and gave the company a “buy” rating in a research report on Monday, August 3rd. Two investment analysts have rated the stock with a Strong Buy rating, twenty-four have assigned a Buy rating and two have assigned a Hold rating to the company’s stock. According to MarketBeat, DexCom currently has a consensus rating of “Buy” and an average price target of $95.50.
View Our Latest Analysis on DexCom
Insider Buying and Selling at DexCom
In related news, EVP Jereme Sylvain sold 3,638 shares of the firm’s stock in a transaction that occurred on Thursday, September 10th. The shares were sold at an average price of $83.27, for a total value of $302,936.26. Following the completion of the transaction, the executive vice president directly owned 146,828 shares of the company’s stock, valued at approximately $12,226,367.56. This trade represents a 2.42% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Michael Brown sold 1,700 shares of DexCom stock in a transaction that occurred on Thursday, October 15th. The shares were sold at an average price of $85.48, for a total transaction of $145,316.00. Following the completion of the transaction, the executive vice president owned 98,185 shares of the company’s stock, valued at $8,392,853.80. This represents a 1.70% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 22,822 shares of company stock worth $1,920,193 over the last three months. Company insiders own 0.28% of the company’s stock.
DexCom Trading Down 1.1%
Shares of DXCM opened at $79.32 on Friday. DexCom, Inc. has a fifty-two week low of $56.72 and a fifty-two week high of $92.59. The business has a 50-day moving average of $83.94 and a 200 day moving average of $75.41. The firm has a market cap of $29.58 billion, a P/E ratio of 31.11, a price-to-earnings-growth ratio of 1.35 and a beta of 1.45. The company has a debt-to-equity ratio of 0.49, a quick ratio of 1.40 and a current ratio of 1.74.
DexCom (NASDAQ:DXCM – Get Free Report) last released its quarterly earnings data on Thursday, October 29th. The medical device company reported $0.73 EPS for the quarter, beating the consensus estimate of $0.68 by $0.05. The business had revenue of $1.34 billion for the quarter, compared to the consensus estimate of $1.33 billion. DexCom had a net margin of 19.42% and a return on equity of 37.77%. The company’s revenue was up 11.1% compared to the same quarter last year. During the same period in the prior year, the firm earned $0.61 earnings per share. As a group, research analysts forecast that DexCom, Inc. will post 2.68 EPS for the current year.
DexCom Company Profile
DexCom, Inc. develops and markets continuous glucose monitoring (CGM) systems for people with diabetes. Its wearable sensors measure glucose levels throughout the day and send readings to compatible receivers or mobile devices, helping users monitor glucose trends and support treatment decisions. The company’s products include its Dexcom G6 and G7 CGM systems, along with software and connected services for users and caregivers. DexCom also offers Stelo, an over-the-counter glucose biosensor designed for adults who do not use insulin.
See Also
- Five stocks we like better than DexCom
- Survey Reveals: How Much Would People Pay for Ribeye Before Giving It Up? [2026]
- If NVIDIA Tightens Its Wallet, These 3 Stocks Could Feel It
- 3 Dividend ETFs Offering Steadier Footing in a Shaky Market
- Lazard’s New ETF Targets Monthly Income With Junk Bonds
Receive News & Ratings for DexCom Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DexCom and related companies with MarketBeat.com's FREE daily email newsletter.
